

Resource Summary Report

Generated by [NIF](#) on Aug 27, 2026

PE/Cyanine7 anti-human CD14

RRID:AB_830690

Type: Antibody

Proper Citation

BioLegend Cat# 325617, RRID:AB_830690

Antibody Information

URL: http://antibodyregistry.org/AB_830690

Proper Citation: BioLegend Cat# 325617, RRID:AB_830690

Target Antigen: CD14

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-human CD14

Description: This monoclonal targets CD14

Target Organism: human

Clone ID: Clone HCD14

Antibody ID: AB_830690

Vendor: BioLegend

Catalog Number: 325617

Alternative Catalog Numbers: 325618

Record Creation Time: 20250820T041941+0000

Record Last Update: 20250820T184024+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-human CD14.

No alerts have been found for PE/Cyanine7 anti-human CD14.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Waclawiczek A, et al. (2026) Leukemic stem cell subtypes determine venetoclax resistance and therapeutic vulnerabilities in AML. *Cell stem cell*, 33(6), 982.

Chen T, et al. (2026) Multi-modal single-cell sequencing reveals network transition in circulating monocytes that aligns with faster recovery in patients with trauma and favours a response to M-CSF. *EBioMedicine*, 130, 106368.

Wang L, et al. (2024) PD-L1-expressing tumor-associated macrophages are immunostimulatory and associate with good clinical outcome in human breast cancer. *Cell reports. Medicine*, 5(2), 101420.

Wu N, et al. (2024) MerTK+ macrophages promote melanoma progression and immunotherapy resistance through AhR-ALKAL1 activation. *Science advances*, 10(40), eado8366.

Jiang Y, et al. (2024) Nicotinamide metabolism face-off between macrophages and fibroblasts manipulates the microenvironment in gastric cancer. *Cell metabolism*, 36(8), 1806.

Rotolo A, et al. (2018) Enhanced Anti-lymphoma Activity of CAR19-iNKT Cells Underpinned by Dual CD19 and CD1d Targeting. *Cancer cell*, 34(4), 596.

Joly-Battaglini A, et al. (2016) Rituximab efficiently depletes B cells in lung tumors??and normal lung tissue. *F1000Research*, 5, 38.